← Every company
Alkermes Plc Patents
What Alkermes Plc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ALKS on carbonthat →Filings on file
27
Granted
3
Still pending
24
Filed under
4 names
27 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| ARIPIPRAZOLE PRODRUG COMPOSITIONA61K 9/0019, A61K 31/496, A61P 25/22, A61P 25/18, A61P 25/24, A61P 25/00, A61K 9/145, A61K 31/00, A61K 45/06, A61K 47/26Filed as Alkermes Pharma Ireland Limited2026-05-01Philip CRESSWELL | pending |
| Substituted Piperidino Compounds and Related Methods of TreatmentC07D 401/04, C07D 401/14, A61P 25/26, C07D 211/58, C07D 211/98, C07D 401/06, C07D 471/04, C07D 487/04, C07D 498/04Filed as Alkermes, Inc.2025-09-22Lewis D. PENNINGTON | pending |
| IMMEDIATE RELEASE MULTILAYER TABLETA61K 9/0063, A61K 31/5513, A61P 25/18, A61P 25/00, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/209, A61K 9/2095, A61K 31/485, A61K 31/551, A61K2300/00Filed as Alkermes Pharma Ireland Limited2025-08-15Renato A. Chiarella | pending |
| Prodrugs of Fumarates and Their Use in Treating Various DiseasesC07D 491/113, A61K 31/4015, C07C 229/12, C07C 229/18, C07C 317/18, C07C 317/28, C07D 207/12, C07D 207/40, C07D 207/408, C07D 211/92, C07D 295/088Filed as Alkermes Pharma Ireland Limited2025-05-16Scott DUNCAN | pending |
| IMMEDIATE RELEASE MULTILAYER TABLETA61K 9/0063, A61K 31/5513, A61P 25/18, A61P 25/00, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/209, A61K 9/2095, A61K 31/485, A61K 31/551, A61K2300/00Filed as Alkermes Pharma Ireland Limited2025-04-25Renato A. Chiarella | pending |
| Pharmaceutical Compositions Having Improved Storage StabilityA61K 47/26, A61K 9/0019, A61K 9/10, A61K 31/496, A61K 31/5513, C07D 215/227, A61P 43/00, A61P 25/18, A61P 25/24, A61P 25/00Filed as ALKERMES PHARMA IRELAND LIMITED2025-04-23Jason M. Perry | pending |
| Aripiprazole Dosing StrategyA61K 31/497, A61P 25/18, A61K 9/0019, A61K 9/0053, A61K 31/496, A61K 47/02, A61K 47/12, A61K 47/26, A61K2300/00Filed as Alkermes Pharma Ireland Limited2025-02-11Lisa L. von Moltke | pending |
| Substituted Fused Bicyclic Compounds and Related Methods of TreatmentC07D 401/14, C07D 417/14, A61P 21/00, A61K 31/454, A61K 31/4545, A61K 31/497, A61K 31/501, A61K 31/506, C07D 401/12, C07D 403/14, C07D 405/14, C07D 413/14, C07D 471/04Filed as Alkermes, Inc.2024-12-17Sudhir Mahadeo HANDE | pending |
| Substituted Fused Bicyclic Compounds and Related Methods of TreatmentC07D 401/14, A61P 21/00, A61K 31/454, A61K 31/4545, A61K 31/497, A61K 31/501, A61K 31/506, A61K 31/5377, C07D 401/12, C07D 405/14, C07D 413/14, C07D 417/14, C07D 471/04Filed as Alkermes, Inc.2024-12-17Sudhir Mahadeo HANDE | pending |
| Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of TreatmentC07D 211/58, C07D 401/04, A61P 21/00, A61P 25/00, A61P 25/26, A61K 31/4468, A61K 31/506, C07D 401/14, C07D 405/04, C07D 405/06, C07D 413/04, C07D 487/10, C07D 491/107Filed as Alkermes, Inc.2024-12-17Sudhir Mahadeo HANDE | pending |
| Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of TreatmentC07D 401/04, A61P 21/00, A61K 31/4468, A61K 31/4523, A61K 31/4525, A61K 31/454, A61K 31/501, A61K 31/5377, C07D 211/58, C07D 401/06, C07D 401/14, C07D 405/06, C07D 413/06, C07D 413/14, C07D 417/06, C07D 487/10, C07D 491/107Filed as Alkermes, Inc.2024-12-17Sudhir Mahadeo HANDE | pending |
| HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERSC07D 215/227, A61P 25/20, A61P 25/28, A61P 43/00, A61P 25/22, A61P 25/18, A61P 25/24, A61P 25/00, A61P 25/16, A61K 31/496, A61K 31/497, C07D 215/22, C07D 241/04, C07D 263/58, C07D 401/12, C07D 401/14, C07D 413/10, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04, C07F 9/6558, C07F 9/65583Filed as Alkermes Pharma Ireland Limited2024-11-14Julius F. Remenar | pending |
| SYNTHESIS OF SUBSTITUTED MACROCYCLIC COMPOUNDSFiled as ALKERMES, INC.2024-10-29BRIAN M. AQUILA | pending |
| Compound For Use In Treating NarcolepsyA61K 31/4353, A61K 31/439, A61K 31/445, A61P 25/00, A61P 25/26, A61K 9/0053, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/4816, A61K 9/4866Filed as Alkermes, Inc.2024-10-18Bhaskar M. REGE | pending |
| COMPOUND FOR USE IN TREATING NARCOLEPSYFiled as ALKERMES, INC.2024-10-18BHASKAR M. REGE | pending |
| Prodrugs of Fumarates and Their Use in Treating Various DiseasesA61K 31/225, C07C 219/08, C07C 229/16, A61P 17/06, A61P 43/00, A61P 25/00, A61K 31/221, C07C 69/60, C07C 219/06, C07C 225/20, C07C 229/12, C07C 233/18, C07C 233/69, C07C 233/91, C07C 235/88, C07C 243/38, C07C 255/24, C07C 271/16, C07C 275/10, C07C 279/08, C07C 309/18, C07C 317/18, C07C 317/28, C07C 327/48, C07C 333/20, C07C 335/16, C07C 337/06, C07D 207/06, C07D 207/10, C07D 207/27, C07D 207/325, C07D 207/34, C07D 207/40, C07D 207/404, C07D 207/408, C07D 207/452, C07D 209/08, C07D 209/48, C07D 209/52, C07D 211/06, C07D 211/38, C07D 211/46, C07D 211/88, C07D 213/64, C07D 213/74, C07D 213/81, C07D 213/85, C07D 213/89, C07D 231/12, C07D 233/42, C07D 233/56, C07D 233/70, C07D 233/74, C07D 235/06, C07D 239/36, C07D 239/54, C07D 239/88, C07D 239/95, C07D 239/96, C07D 249/04, C07D 249/08, C07D 257/04, C07D 263/04, C07D 263/22, C07D 265/30, C07D 265/32, C07D 265/33, C07D 277/42, C07D 279/12, C07D 295/088, C07D 295/108, C07D 295/205, C07D 295/24, C07D 317/66, C07D 491/08, C07D 491/113, C07D 491/18, C07D 493/08Filed as Alkermes Pharma Ireland Limited2024-07-23Tarek A. Zeidan | pending |
| Compound For Use In Treating NarcolepsyFiled as Alkermes, Inc.2024-07-12Bhaskar M. REGE | pending |
| Substituted Macrocyclic Compounds and Related Methods of TreatmentC07D 498/04, C07D 498/08, A61P 43/00, A61P 25/00, A61P 25/08, A61P 25/26, A61K 31/4353, A61K 31/439, C07B2200/05, C07D 498/14, C07D 498/18, C07D 498/22Filed as Alkermes, Inc.2024-06-17Lewis D. PENNINGTON | pending |
| Monomethylfumarate Prodrug CompositionsA61K 9/2846, A61K 9/2009, A61K 9/2013, A61K 9/2027, A61K 9/2054, A61K 9/2072, A61K 9/2813, A61K 9/282, A61K 9/2893, A61K 9/4808, A61K 9/5026, A61K 31/225, A61K 31/397, A61K 31/40, A61K 31/4015, A61K 31/403, A61K 31/4035Filed as Alkermes Pharma Ireland Limited2024-05-01David S. MANSER | pending |
| Compound For Use In Treating NarcolepsyFiled as Alkermes, Inc.2024-04-08Bhaskar M. REGE | pending |
| Substituted Macrocyclic Compounds and Related Methods of TreatmentC07D 498/04, A61P 25/10, A61P 25/00, A61K 31/4353, C07D 498/14Filed as Alkermes, Inc.2024-04-05Lewis D. PENNINGTON | 12753188 |
| Compound For Use In Treating NarcolepsyFiled as Alkermes, Inc.2024-04-02Bhaskar M. REGE | pending |
| Pharmaceutical Compositions Having Improved Storage StabilityA61K 47/26, A61K 9/0019, A61K 9/10, A61K 31/496, A61K 31/5513, C07D 215/227Filed as ALKERMES PHARMA IRELAND LIMITED2024-03-27Jason M. Perry | 12311027 |
| ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDSA61K 9/0019, A61K 31/00, A61K 31/496, A61P 25/22, A61P 25/18, A61P 25/24, A61P 25/00, A61K 9/10, A61K 47/26Filed as ALKERMES PHARMA IRELAND LIMITED2024-02-13Magali B. Hickey | 12653822 |
| Sustained Release Aminopyridine CompositionA61K 31/4409, A61K 9/20, A61K 9/2054, A61K 9/2077, A61K 31/44, A61K 47/12, A61K 47/14, A61K 47/38, A61K 47/44Filed as Alkermes Pharma Ireland Limited2024-01-12Sean Cunningham | pending |
| Prodrugs of Fumarates and Their Use in Treating Various DiseasesC07D 491/113, A61K 31/4015, C07C 229/12, C07C 229/18, C07C 317/18, C07C 317/28, C07D 207/12, C07D 207/40, C07D 207/408, C07D 211/92, C07D 295/088Filed as Alkermes Pharma Ireland Limited2024-01-11Scott Duncan | pending |
| COMPOUND FOR USE IN TREATING NARCOLEPSYFiled as Alkermes, Inc.2024-01-05Bhaskar M. Rege | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on ALKS
Company overviewEverything on ALKS in one place, with the price.SEC filingsWhat ALKS's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ALKS's own officers and directors buy and sell.Executive payWhat ALKS awarded its chief executive, and what it became.LobbyingWhat ALKS spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on ALKS's account, and who they worked for.